Cite
APA Citation
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Knöbl, P., Cataland, S., De Beuf, K., Callewaert, F., De Winter, H., & Zeldin, R. K. (2017). caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15, 1448–1452. http://access.bl.uk/ark:/81055/vdc_100047420017.0x000011